Eclipse Life Sciences Reports Positive Phase 2 Drug Data
The company showed improvement in key vision metrics for its EC-104 corticosteroid implant in a recent clinical trial.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Do you believe medical treatments for chronic conditions like vision loss are becoming more manageable?
Durham-based Eclipse Life Sciences announced positive results from its BETTIS-1 Phase 2 clinical trial for the EC-104 intravitreal implant. The study demonstrated improvement in visual acuity and retinal thickness for patients who had previously responded poorly to anti-VEGF therapy.
Why it matters
The EC-104 implant is designed to provide sustained drug release for six months, which aims to reduce the significant treatment burden for patients currently requiring frequent, recurring eye injections.
The EC-104 implant is a biodegradable corticosteroid designed for approximately six months of drug release. The trial observed participants over 24 weeks to reach its primary endpoints.
The players
Eclipse Life Sciences
A biotechnology firm headquartered in Research Triangle Park that specializes in developing innovative ophthalmic treatments.
The details
The BETTIS-1 trial evaluated the biodegradable implant against the standard treatment, Ozurdex, in subjects with a history of suboptimal responses to anti-VEGF therapy. The data showed that the device successfully met its primary endpoint for safety during the observation period.
Timeline
October 15, 2026: The company announced the trial results.
24 weeks: The duration of the trial observation for primary endpoints.
2027: The company plans to initiate a pivotal Phase 3 program.
The Tech Race
This development represents a shift toward long-acting ocular drug delivery systems that aim to replace the limitations of legacy anti-VEGF therapy. It positions the company as a competitor in the ophthalmic space by addressing the high injection frequency required by older treatments.
Patients who struggle with the regimen of frequent eye injections may eventually see a reduction in treatment frequency if this implant reaches the market. The technology aims to provide a six-month continuous therapeutic window, which could significantly streamline care routines.
The takeaway
The successful Phase 2 results offer a potential path toward less invasive management for chronic eye conditions. Continued monitoring of the 2027 Phase 3 trial initiation will be necessary to gauge the commercial viability of this long-acting implant.
What happens next
Eclipse Life Sciences plans to present full clinical data at an upcoming ophthalmology conference, and the company intends to launch a pivotal Phase 3 program in 2027.
Further reading
For more industry updates, visit our Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe medical treatments for chronic conditions like vision loss are becoming more manageable?
